Amundi Asset Management US’s AbbVie ABBV Stock Holding History

Amundi Asset Management US’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$642M	Buy	5,927,925 +134,093	+2%	+$14.3M	0.49%	42
2020 Q4	$621M	Buy	5,793,832 +805,938	+16%	+$77.4M	0.53%	38
2020 Q3	$437M	Sell	4,987,894 -55,863	-1%	-$5.26M	0.46%	45
2020 Q2	$495M	Buy	5,043,757 +207,343	+4%	+$18.3M	0.59%	28
2020 Q1	$238M	Sell	4,836,414 -282,544	-6%	-$24.1M	0.42%	55
2019 Q4	$453M	Buy	5,118,958 +1,062,262	+26%	+$88.2M	0.53%	39
2019 Q3	$307M	Buy	4,056,696 +429,761	+12%	+$29.5M	0.46%	41
2019 Q2	$1.8B	Sell	3,626,935 -271,864	-7%	-$21.4M	1.47%	5
2019 Q1	$314M	Buy	3,898,799 +585,248	+18%	+$47.9M	0.44%	55
2018 Q4	$305M	Buy	3,313,551 +587,048	+22%	+$51.6M	0.28%	51
2018 Q3	$258M	Buy	2,726,503 +1,483,527	+119%	+$141M	0.34%	69
2018 Q2	$115M	Sell	1,242,976 -103,145	-8%	-$10.1M	0.17%	139
2018 Q1	$127M	Sell	1,346,121 -50,091	-4%	-$5.5M	0.2%	121
2017 Q4	$135M	Buy	+1,396,212	New	+$132M	0.21%	124
2017 Q1	–	Sell	-112,829	Closed	-$7.07M	–	523
2016 Q4	$7.07M	Sell	112,829 -1,018,165	-90%	-$62.1M	0.02%	348
2016 Q3	$71.3M	Sell	1,130,994 -150,956	-12%	-$9.77M	0.26%	88
2016 Q2	$79.4M	Buy	1,281,950 +20,516	+2%	+$1.25M	0.29%	89
2016 Q1	$72.1M	Buy	1,261,434 +111,360	+10%	+$6.21M	0.27%	88
2015 Q4	$68.1M	Sell	1,150,074 -1,136,888	-50%	-$65.5M	0.25%	102
2015 Q3	$124M	Sell	2,286,962 -414,655	-15%	-$27M	0.51%	58
2015 Q2	$182M	Buy	2,701,617 +333,476	+14%	+$21.8M	0.66%	34
2015 Q1	$139M	Sell	2,368,141 -734,052	-24%	-$44.3M	0.5%	59
2014 Q4	$203M	Buy	3,102,193 +500,357	+19%	+$31.5M	0.74%	27
2014 Q3	$150M	Buy	2,601,836 +587,255	+29%	+$32.6M	0.57%	48
2014 Q2	$114M	Sell	2,014,581 -31,095	-2%	-$1.63M	0.44%	74
2014 Q1	$105M	Buy	2,045,676 +8,573	+0.4%	+$433K	0.4%	76
2013 Q4	$108M	Sell	2,037,103 -2,406	-0.1%	-$118K	0.41%	75
2013 Q3	$91.2M	Sell	2,039,509 -22,842	-1%	-$1.01M	0.37%	81
2013 Q2	$85.3M	Buy	+2,062,351	New	+$90.2M	0.36%	89

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Amundi Asset Management US's ABBV Position: Q1 2021 in Review

Amundi Asset Management US increased its AbbVie (ABBV) stake by 2.3% in Q1 2021, buying an estimated $14.3M and bringing the position to 5,927,925 shares worth $642M. The position accounts for 0.49% of the portfolio, ranked #42.

Amundi Asset Management US first reported a position in ABBV in Q2 2013 and has held it in 29 quarters since. The position peaked at $1.8B in Q2 2019. 2,615 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

Amundi Asset Management US held 5,927,925 shares of AbbVie worth $642M as of Q1 2021.
Amundi Asset Management US bought 134,093 AbbVie shares in Q1 2021, an estimated $14.3M.
AbbVie made up 0.49% of Amundi Asset Management US's portfolio in Q1 2021, its #42 holding.
Amundi Asset Management US first reported a position in AbbVie in Q2 2013 and has held it in 29 quarters since.
Amundi Asset Management US's AbbVie position peaked at $1.8B in Q2 2019.
2,615 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.